Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale
暂无分享,去创建一个
I. Wilkinson | M. Kostapanos | J. Cheriyan | K. Maki-Petaja | P. Cacciottolo | H. Pavey | A. Hubsch | James B. Hurlock